Moteur de recherche d’entreprises européennes

Financement de l’UE (12 M €) : Patient de l’UE - Clinique centrale pLatform Hor01/11/2019 Programme de recherche et d'innovation de l'UE « Horizon »

Vue d’ensemble

Texte

Patient de l’UE - Clinique centrale pLatform

EU-PEARL has the ambition of transforming the current approach of conducting single-compound clinical trials into the use of cross-company Integrated Research Platforms (IRPs), taking into consideration both patients’ interests and the opportunities from novel molecules for addressing medical needs. Patient-centric data and knowledge sharing have the potential to accelerate the development of new treatments and reduce the operational costs of clinical trials. EU-PEARL will improve clinical effectiveness, patients’ satisfaction and societal access to timely and affordable medicines and it will shape the clinical trials of the future. This will change the industry paradigm from competition to cooperation in four disease areas and provide the framework for designing IRPs in other disease areas. The main objectives of EU-PEARL are: (1) To create a reusable, accessible and sustainable modular IRP for the design and execution of patient-centric, cross- company IRP in any disease area with unmet needs; (2) To set up the open, dynamic, patient inclusive IRP governance structure that will manage the appropriate regulatory, ethical, legal, statistical and data utilisation requirements of the IRP; (3) To disseminate and exploit the EU-PEARL paradigm through the provision of the necessary common tools, procedures, expertise and operational skills working to the highest scientific, regulatory and ethical standards and best practices, developed jointly by public and industry partners in a consensus-based approach; and (4) To create trial-ready IRP networks in the four disease areas of Major Depressive Disorder (MDD), Tuberculosis (TB), Non-Alcoholic Steatohepatitis (NASH) and Neurofibromatosis (NF).


Abbvie Inc. 0,00 €
Allergan Ltd. 0,00 €
Assistance Publique Hopitaux de Paris 619 749 €
Astrazeneca AB 0,00 €
BUNDESINSTITUT für IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL 317 625 €
Berry Consultants LLP 196 250 €
CHARITE - UNIVERSITAETSMEDIZIN BERLIN 539 000 €
?????????? ????? ?????????? 0,00 €
Custodix N.V. 106 248 €
?????????? ?? 129 158 €
EUROPEAN AIDS TREATMENT GROUP e. V. 0,00 €
EUROSCAN INTERNATIONAL NETWORK e. V. 117 500 €
?????? ???? 775 625 €
Ecrin European Clinical Research Infrastructure Network 426 875 €
Erasmus Universitair Medisch Centrum Rotterdam 899 875 €
Fondation Cardiometabolisme Nutrition 0,00 €
Forum des Patients Europeens 459 250 €
Fundacio Hospital Universitari Vall D'Hebron - Institut de Recerca 2 182 245 €
Global Alliance FOR TB Drug Development NON Profit Organisation 0,00 €
Information Technology FOR Translational Medicine (Ittm) SA 184 970 €
Institut de Recherches Internationales Servier Iris 0,00 €
Janssen Pharmaceutica N.V. 0,00 €
Katholieke Universiteit Leuven 186 375 €
King's College London 612 078 €
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN 274 750 €
Medizinische Universitaet Wien 831 375 €
NOVARTIS PHARMA AG 0,00 €
Novo Nordisk A/S 0,00 €
OTSUKA NOVEL PRODUCTS GmbH 0,00 €
Pfizer Ltd. 0,00 €
Sanofi-Aventis Recherche & Developpement 0,00 €
Springworks Therapeutics Inc. 0,00 €
Synapse Research Management Partners SL 97 700 €
TEVA PHARMACEUTICAL INDUSTRIES Ltd. 0,00 €
THE European Institute for Innovation Through Health Data 751 625 €
Teamit Research SL 985 181 €
The Chancellor, Masters and Scholars of the University of Oxford 114 625 €
The University of Manchester 40 000 €
Universita Degli Studi DI Milano 145 250 €
Universita Vita-Salute SAN Raffaele 734 250 €
University of Newcastle Upon Tyne 277 375 €

https://cordis.europa.eu/project/id/853966

Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.

Creative Commons License Les visualisations de "Abbvie Inc. - Financement de l’UE (12 M €) : Patient de l’UE - Clinique centrale pLatform" sont mis à disposition par North Data et peuvent être réutilisées selon les termes de la licence Creative Commons CC-BY.